• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Labcorp Appoints Google Cloud Executive Kirsten Kliphouse to Its Board of Directors

    10/13/22 4:30:00 PM ET
    $LH
    Medical Specialities
    Health Care
    Get the next $LH alert in real time by email

    Labcorp (NYSE:LH), a leading global life sciences company, today announced that Kirsten Kliphouse, president of Americas, Google Cloud, has joined its Board of Directors as an independent member.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221013006001/en/

    Photo courtesy of Labcorp

    Photo courtesy of Labcorp

    Kliphouse brings decades of leadership experience honed at some of the world's most-recognizable technology companies, as well as a proven passion for building teams and customer relationships. At Google Cloud, Kliphouse is focused on harnessing technology and the collective power of her teams to help enterprises, mid-market customers, and small and mid-sized businesses find innovative solutions to complex challenges.

    "Labcorp has a long history of leveraging science and technology to advance innovations and create a healthier world," said Adam Schechter, chairman and CEO of Labcorp. "Kirsten's leadership and depth in the technology sector and experience with large, global organizations will bring unique and valuable perspectives to our Board and Labcorp. We are thrilled to welcome Kirsten to our Board."

    Prior to joining Google Cloud, Kliphouse served as a senior vice president and general manager at Red Hat, Inc., where she led the company's North American commercial sales operations. She has also served as CEO of Yardarm Technologies, a firearm safety and tracking firm, and has advised numerous startups on product strategy. In addition, Kliphouse spent 25 years at Microsoft—beginning as an account manager and regularly moving into more senior leadership roles throughout her tenure. Before her departure, Kliphouse oversaw a team of more than 10,000 people as corporate vice president of global customer service and support.

    "Labcorp's commitment to harnessing science, technology and innovation to generate insights that support more-informed health and treatment decisions is a source of inspiration," Kliphouse said. "I'm incredibly grateful for the opportunity to join such a dedicated group of individuals, share my experiences and support the company's important work."

    About Labcorp

    Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With over 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE:LH) reported revenue of $16 billion in FY2021. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements, including but not limited to statements with respect to the Company's leadership, future operations and opportunities for future growth.

    Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.

    The company has no obligation to provide any updates to forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221013006001/en/

    Get the next $LH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LH

    DatePrice TargetRatingAnalyst
    7/10/2025$260.00Buy → Hold
    HSBC Securities
    4/2/2025$276.00Buy
    Redburn Atlantic
    3/4/2025$250.00 → $300.00Neutral → Buy
    Citigroup
    1/7/2025$260.00 → $265.00In-line → Outperform
    Evercore ISI
    12/10/2024$265.00 → $275.00Buy
    Jefferies
    10/30/2024Hold → Buy
    HSBC Securities
    10/1/2024$235.00Neutral
    Piper Sandler
    3/25/2024$250.00Hold → Buy
    Argus
    More analyst ratings

    $LH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Van Der Vaart Sandra D exercised 3,903 shares at a strike of $131.43 and sold $1,059,371 worth of shares (3,903 units at $271.42) (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/15/25 10:55:59 AM ET
    $LH
    Medical Specialities
    Health Care

    President & CEO Schechter Adam H sold $1,505,440 worth of shares (5,643 units at $266.78), decreasing direct ownership by 6% to 93,319 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/13/25 12:29:58 PM ET
    $LH
    Medical Specialities
    Health Care

    Director Gilliland Dwight Gary sold $529,900 worth of shares (2,000 units at $264.95), decreasing direct ownership by 23% to 6,656 units (SEC Form 4)

    4 - LABCORP HOLDINGS INC. (0000920148) (Issuer)

    8/1/25 8:44:32 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Labcorp Holdings Inc. downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Labcorp Holdings Inc. from Buy to Hold and set a new price target of $260.00

    7/10/25 9:03:30 AM ET
    $LH
    Medical Specialities
    Health Care

    Redburn Atlantic initiated coverage on Labcorp Holdings Inc. with a new price target

    Redburn Atlantic initiated coverage of Labcorp Holdings Inc. with a rating of Buy and set a new price target of $276.00

    4/2/25 8:50:29 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. upgraded by Citigroup with a new price target

    Citigroup upgraded Labcorp Holdings Inc. from Neutral to Buy and set a new price target of $300.00 from $250.00 previously

    3/4/25 7:36:42 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    SEC Filings

    View All

    SEC Form 144 filed by Labcorp Holdings Inc.

    144 - LABCORP HOLDINGS INC. (0000920148) (Subject)

    8/11/25 9:50:12 AM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Labcorp Holdings Inc.

    10-Q - LABCORP HOLDINGS INC. (0000920148) (Filer)

    8/1/25 1:25:28 PM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LABCORP HOLDINGS INC. (0000920148) (Filer)

    7/24/25 6:52:21 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

    Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based in-vitro diagnostic (IVD) test cleared by the U.S. Food and Drug Administration (FDA) to aid in the diagnosis of Alzheimer's disease through early detection of the amyloid plaques associated with the disease in appropriate patients. Developed by Fujirebio Diagnostics, Inc., the test is now available nationwide through Labcorp.

    8/18/25 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

    Test Finder interprets provider questions in context to deliver curated, clinically relevant results, going beyond traditional search Developed in collaboration with Amazon Web Services, Test Finder is now available on Labcorp.com BURLINGTON, N.C., July 30, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Test Finder, a first-of-its-kind generative AI tool developed with Amazon Web Services (AWS). Designed to simplify lab test selection, Test Finder enables healthcare providers to ask questions or describe conditions in plain language and receive curated test recommendations—enhancing the user experienc

    7/30/25 7:12:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

    First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C., July 29, 2025 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been CE-marked under the European Union's (EU) new In Vitro Diagnostic Regulation (IVDR). It is now the first and only test of its kind in the EU CE-marked for comprehensive solid tumor profiling. This marks a significant milestone in expanding access to personalized treatment options for the approximately 2.7 million people diagnosed with cancer every year in the EU

    7/29/25 7:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Financials

    Live finance-specific insights

    View All

    Labcorp Announces 2025 Second Quarter Results

    Raises Full-Year Guidance Financial results from Operations for second quarter 2025 versus second quarter 2024:Revenue: $3.53 billion versus $3.22 billionDiluted EPS: $2.84 versus $2.43Adjusted EPS: $4.35 versus $3.94Raised Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance:Revenue guidance narrowed to 7.5% to 8.6%; midpoint raised by 70 basis pointsAdjusted EPS range narrowed to $16.05 to $16.50; midpoint raised by $0.23Free Cash Flow range of $1.13 billion to $1.28 billion; midpoint raised by $25 millionBroadened our partnerships with hospitals, health systems and regional/local labs and enhanced access to comprehensive testing and laboratory servicesIntroduced several new tests

    7/24/25 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp Declares Quarterly Dividend

    BURLINGTON, N.C., July 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on September 11, 2025, to stockholders of record as of the close of business on August 28, 2025. About LabcorpLabcorp (NYSE:LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and

    7/10/25 6:50:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp to Announce Second Quarter Financial Results on July 24, 2025

    BURLINGTON, N.C., June 26, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE:LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 2025 before the market opens on Thursday, July 24, 2025. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor Relations website. Participan

    6/26/25 4:10:00 PM ET
    $LH
    Medical Specialities
    Health Care

    $LH
    Leadership Updates

    Live Leadership Updates

    View All

    Privia Health Announces Appointment of Lance V. Berberian to its Board of Directors

    ARLINGTON, Va., July 08, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced the appointment of Lance V. Berberian to its Board of Directors, effective July 15, 2025. He has also been named a member of the Audit Committee of the Board. Following the appointment of Mr. Berberian, the Board will comprise 10 directors. "We are excited to welcome Lance to our Board of Directors," said David King, Chairman of the Board, Privia Health Group, Inc. "Lance brings extensive technology strategy and digital transformation experience to the Board, including IT governance, infrastructure management and cybersecurity. We believe his expertise will be invaluable to Privia Health as

    7/8/25 9:00:00 AM ET
    $LH
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    SOLVD Health Appoints Mike Aicher and Vince Cebula to Board of Directors to Support Next Phase of Growth

    SOLVD Health (SOLVD), a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has appointed diagnostics pioneer Mike Aicher and strategic advisor Vince Cebula to its Board of Directors. Their combined leadership in molecular diagnostics, healthcare technology, and growth-stage investment will support the company's continued expansion as it scales access to personalized health insights and accelerates development of its precision diagnostics platform. Aicher's expertise in building and scaling diagnostic platforms will be instrumental as SOLVD Health expands its personalized health solutions. He brings more than three decades of executiv

    5/12/25 9:00:00 AM ET
    $LH
    Medical Specialities
    Health Care

    Labcorp CFO Glenn Eisenberg Announces Plans to Retire

    Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.

    11/19/24 7:00:00 AM ET
    $BGNE
    $LH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    $LH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/13/24 5:08:06 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Laboratory Corporation of America Holdings (Amendment)

    SC 13D/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Filed by)

    7/24/23 4:20:26 PM ET
    $LH
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - LABORATORY CORP OF AMERICA HOLDINGS (0000920148) (Subject)

    2/10/21 11:14:27 AM ET
    $LH
    Medical Specialities
    Health Care